Publications by authors named "E Buntinx"
Background: Respiratory syncytial virus (RSV) causes a significant disease burden in adults with chronic comorbidities. Rates of severe RSV disease and death are as high, or higher in younger adults with risk factors than in healthy older adults in whom RSV vaccination is recommended. We conducted an immunobridging study using the Ad26/protein RSV preF vaccine, which previously demonstrated efficacy in adults aged ≥65 years to support extrapolation of efficacy demonstrated in an older population to younger adult populations at high risk of severe RSV disease.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the safety, tolerability, and effectiveness of V116, a new 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults, contrasting it with the existing PCV20.
- Conducted as a phase 3 trial across 112 clinical sites in 11 countries, participants were divided into two cohorts: those aged 50 and older and those aged 18-49, receiving either V116 or PCV20 through random assignment.
- The research focuses on four primary immunogenicity outcomes, comparing the immune responses between V116 and PCV20 to determine if V116 is non-inferior or superior, emphasizing its potential advantages for specific pneumococcal serotypes
Article Synopsis
- SCB-2019, a COVID-19 vaccine candidate, was tested in a study involving 1,278 healthy adolescents aged 12-17 across Belgium, Colombia, and the Philippines to evaluate its immunogenicity and safety compared to placebo.
- The vaccine showed strong immunogenicity, with neutralizing antibody levels in adolescents comparable to those in young adults, particularly for those previously exposed to SARS-CoV-2.
- The SCB-2019 vaccine was well tolerated, with mild to moderate side effects that were similar between adolescents receiving the vaccine and those given a placebo, except for more reported injection site pain in the vaccine group.
Background: We evaluated immunogenicity of SCB-2019, a subunit vaccine candidate containing a pre-fusion trimeric form of the SARS-CoV-2 spike (S)-protein adjuvanted with CpG-1018/alum.
Methods: The phase 2/3, double-blind, randomized SPECTRA trial was conducted in five countries in participants aged ≥ 18 years, either SARS-CoV-2-naïve or previously exposed. Participants were randomly assigned to receive two doses of SCB-2019 or placebo administered intramuscularly 21 days apart.
Article Synopsis
- The study evaluated the safety and efficacy of the SCB-2019 COVID-19 vaccine in a large, double-blind, placebo-controlled trial involving over 30,000 adults across five countries.* -
- Participants were randomly assigned to receive either the vaccine or a placebo, and the primary focus was on measuring vaccine effectiveness against COVID-19 and monitoring adverse effects.* -
- Results showed that the vaccine had an overall efficacy of 67.2% against any severity of COVID-19, and 83.7% efficacy against moderate-to-severe cases, indicating its potential effectiveness in preventing the disease.*